2.345

3.76% +0.085

Genprex Inc (GNPX)

Overview News Price History Option Chain Financials Discussions Forecast

Genprex Inc stock is currently priced at $2.345, with a 24-hour trading volume of 8,754. It has seen a +3.76% increased in the last 24 hours and a -17.43% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.29 pivot point. If it approaches the $2.40 resistance level, significant changes may occur.

Previous Close:

$2.26

Open:

$2.3501

24h Volume:

8,754

Market Cap:

$4.32M

Revenue:

Net Income/Loss:

$-31.45M

P/E Ratio:

-3.7823

EPS:

-0.62

Net Cash Flow:

$-24.56M

1W Performance:

+10.61%

1M Performance:

-17.43%

6M Performance:

+835.75%

1Y Performance:

+200.56%

1D Range:

$2.2726

$2.36

52W Range:

$0.19

$8.396

Genprex Inc Stock (GNPX) Company Profile

Name

Genprex Inc

Sector

Healthcare (1193)

Industry

Biotechnology (685)

Phone

877 774 4679

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX

Employee

Twitter

@genprex

Next Earnings Date

2024-05-22

Latest SEC Filings

GNPX's Discussions on Twitter

Genprex Inc Stock (GNPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-21	Initiated	National Securities	Buy
Apr-29-19	Initiated	Noble Capital Markets	Outperform

Genprex Inc Stock (GNPX) Latest News

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

Zacks Investment Research

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Dow Turns Lower; Federal Reserve Keeps Rates Unchanged

Benzinga

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results

Benzinga

Genprex Inc Stock (GNPX) Financials Data

Genprex Inc (GNPX) Net Income 2024

GNPX net income (TTM) was -$31.45 million for the quarter ending September 30, 2023, a -31.24% decrease year-over-year.

Genprex Inc (GNPX) Cash Flow 2024

GNPX recorded a free cash flow (TTM) of -$24.56 million for the quarter ending September 30, 2023, a -50.03% decrease year-over-year.

Genprex Inc (GNPX) Earnings per Share 2024

GNPX earnings per share (TTM) was -$24.40 for the quarter ending September 30, 2023, a -22.00% decline year-over-year.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.